N-Methylmoranoline

• CAT Number: R000223
• CAS Number: 69567-10-8
• Molecular Formula: C7H15NO4
• Molecular Weight: 177.20
• Purity: ≥95%
• Synonyms: (2R,3R,4R,5S)-2-(hydroxymethyl)-1-methylpiperidine-3,4,5-triol
• InChI: InChI=1S/C7H15NO4/c1-8-2-5(10)7(12)6(11)4(8)3-9/h4-7,9-12H,2-3H2,1H3/t4-,5+,6-,7-/m1/s1
• InChIKey: AAKDPDFZMNYDLR-XZBKPIIZSA-N
• SMILES: CN1CC(C(C(C1CO)O)O)O

N-Methylmoranoline (MOR 14) is an α-glucosidase inhibitor.
N-Methylmoranoline dose-dependently decreases the α-1,6-glucosidase activity in rabbit heart extract. The myocardial uptake of a considerable amount of N-Methylmoranoline is sufficient to fully inhibit alpha-1,6-glucosidase. Preischemic treatment with 25, 50, and 100 mg/kg of N-Methylmoranoline dose-dependently reduces the infarct size without altering the blood pressure or heart rate[1]. MOR-14 significantly increases levels of PKC-ε in the particulate fraction at 20 and 30 min of ischaemia and in the cytosolic fraction at 30 min of ischaemia[2].
N-Methylmoranoline decreases the alpha-1,6-glucosidase activity to approximately 20%, reduces the glycogen breakdown, and attenuates the lactate accumulation at both 10 and 30 minutes of ischemia[1]. MOR-14 is protective against postischemic left ventricular dysfunction through the inhibition of glycogenolysis in the isolated rat heart[3].

Reference

[1]. Arai M, et al. N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly reduced infarct size in rabbit hearts. Circulation. 1998 Apr 7;97(13):1290-7.
 [Content Brief]

[2]. Arai M, et al. Role of protein kinase C in the reduction of infarct size by N-methyl-1-deoxynojirimycin, an alpha-1,6-glucosidase inhibitor. Br J Pharmacol. 2001 Jul;133(5):635-42.
 [Content Brief]

[3]. Nishida Y, et al. N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly improves postischemic left ventricular dysfunction. Heart Vessels. 2000;15(6):268-73.
 [Content Brief]